Filing summary
Entity discrepancy: The request identifies Gridai Technologies Corp., but the supplied 10-Q is for First Wave BioPharma, Inc. (Nasdaq: FWBI). This summary reflects the filing provided. Reporting period: quarter ended March 31, 2023; filed May 12, 2023. Financial statements are unaudited.
Business context and operating outlook
First Wave is a clinical-stage biotechnology company developing gut-restricted therapies, principally adrulipase for exocrine pancreatic insufficiency and niclosamide for gastrointestinal conditions. The company reported no revenue to date. It initiated a Phase 2b adrulipase monotherapy trial in Q1 2023 and expected topline data in Q3 2023. The COVID-19 GI niclosamide program was discontinued after mixed results; the ulcerative proctitis/proctosigmoiditis program received fewer resources, and the ICI-associated colitis program was on hold because of financial constraints.
Financial results and liquidity
- Revenue and margins: No revenue was reported; gross margin and operating margin are not meaningful for this quarter.
- Expenses and loss: Operating expenses were $4.06 million, down 57% from $9.38 million in Q1 2022. R&D was $1.36 million, down 73%; G&A was $2.70 million, down 39%. Net loss was $4.07 million versus $9.63 million; loss applicable to common shareholders was $4.16 million. Basic and diluted loss per share was $1.82 versus $138.28, with share counts substantially affected by reverse splits and financing activity.
- Cash flow: Operating cash use was $2.85 million versus $7.91 million. Financing provided $3.55 million, primarily from the March 2023 private placement, versus $5.37 million in Q1 2022. Cash, cash equivalents and restricted cash increased $0.70 million to $2.09 million.
- Balance sheet and liquidity: At March 31, cash and cash equivalents were $2.06 million; working capital was approximately $0.9 million; total assets were $5.53 million and total liabilities were $2.82 million. The company had an accumulated deficit of $172.6 million. Current note payable was $380,390; operating lease liabilities totaled $264,460. Management expected available cash to fund planned operations only through June 2023 and stated substantial doubt existed about the company’s ability to continue as a going concern without additional funding.
- Financing and dilution: The March 2023 private placement generated approximately $3.77 million net proceeds and included common stock, pre-funded warrants and warrants. At quarter-end, 4.69 million warrants were outstanding. Common shares outstanding were 1.55 million at March 31 and 1.81 million as of May 10, 2023; the filing also reports substantial potential share issuance from warrants and other awards.
Material changes versus Q1 2022
Operating expenses and net loss declined substantially, primarily reflecting lower clinical-trial spending and lower public-company, personnel, professional-fee and insurance costs. Operating cash use also fell. Financing proceeds were lower than in Q1 2022, and the company’s ending cash balance was $2.09 million versus $5.69 million a year earlier. The company completed a 1-for-7 reverse stock split in January 2023 and reported regaining Nasdaq minimum-bid-price compliance in February; the Nasdaq Panel’s oversight process was closed.
Guidance, risks, contingencies and unusual items
- Management expected R&D and G&A expenses to remain stable for the rest of 2023, while emphasizing the need for additional capital. The company noted that spending changes could affect the timing of its funding need.
- On April 21, 2023, the company agreed to pay a clinical research organization $600,000 over six months to settle disputes over two clinical trial agreements; the full liability was recorded at March 31, 2023.
- A director’s Delaware lawsuit sought approximately $200,000 in advancement of legal expenses; trial was scheduled for May 2023. The supplied filing text does not provide an outcome.
- Settlement terms relating to the FWB acquisition leave potential future milestone and revenue-share obligations tied to adrulipase and niclosamide; these were not accrued because they were not considered probable.
- Key risks include clinical and regulatory uncertainty, need for further equity or debt financing, potential inability to continue as a going concern, manufacturing and supply risks, and continued Nasdaq-listing compliance. The company said there were no material changes to the risk factors in its 2022 Form 10-K.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing is First Wave BioPharma, not Gridai Technologies Corp.
- Check subsequent financing, cash runway and operating status after the stated June 2023 funding horizon.
- Verify the Phase 2b adrulipase trial progress and whether topline data were reported as expected in Q3 2023.
- Review the dilution and exercise terms of the outstanding warrants, pre-funded warrants and equity awards.
- Confirm payment of the $600,000 CRO settlement and the outcome of the director’s legal-expense case.